Supernus Pharm (SUPN) Posts Mixed Q2 Results

Supernus Pharm (NASDAQ: SUPN) reported Q2 EPS of ($5.17), $4.71 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $750 thousand versus the consensus estimate of $70 thousand.

For earnings history and earnings-related data on Supernus Pharm (SUPN) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• BMO starts chip stocks coverage: Here are its preferred picks
• CoStar Group acquires Zonda for $800M, adding new home data